Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans

Glycobiology

Volumn 20, Issue 7, 2010, Pages 812-823

  Dunlop, D Cameron ^a   Bonomelli, Camille ^a   Mansab, Fatma ^a   Vasiljevic, Snezana ^a   Doores, Katie J ^b   Wormald, Mark R ^a   Palma, Angelina S ^c   Feizi, Ten ^c   Harvey, David J ^a   Dwek, Raymond A ^a   Crispin, Max ^a   Scanlan, Christopher N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Scripps Research Mstitute   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

2G12; Glycan array; GnT I deficient HEK 293S; Human immunodeficiency virus; Kifunensine; Oligomannose; Vaccine; Yeast

Indexed keywords

ANTIGEN; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; KIFUNENSINE; MANNAN; MANNOSE; MANNOSE OLIGOSACCHARIDE; MANNOSYLTRANSFERASE; MONOCLONAL ANTIBODY 2G12; POLYSACCHARIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; CROSS REACTION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SERUM; VIRUS NEUTRALIZATION; WILD TYPE; YEAST; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; SACCHAROMYCES CEREVISIAE;

ANTIBODIES, NEUTRALIZING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; MANNOSE; MOLECULAR MIMICRY;

EID: 77956366187     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwq020     Document Type: Article

References (54)

1. Aricescu AR, Lu W, Jones EY. 2006. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystattogr D Biol Crystallogr. 62: 1243-1250.
2. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR. 2008. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immuno-deficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol. 82: 6359-6368.
3. Ballou CE. 1990. Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods Enzymol. 185: 440-470.
4. Blixt O, Head S, Mondala T, Scanlan C, Huflejt ME, Alvarez R, Bryan MC, Fazio F, Calarese D, Stevens J, Razi N, Stevens DJ, Skehel JJ, van Die I, Burton DR, Wilson IA, Cummings R, Bovin N, Wong CH, Paulson JC. 2004. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci USA. 101: 17033-17038.
5. Börnsen KO, Mohr MD, Widmer HM. 1995. Ion exchange and purification of carbohydrates on a Nafion(r) membrane as a new sample pretreatment for matrix- assisted laser desorption-ionization mass spectrometry. Rapid Commun Mass Spectrom. 9: 1031-1034.
6. Bowden TA, Crispin M, Graham SC, Harvey DJ, Grimes JM, Jones EY, Stuart DI. 2009. Unusual molecular architecture of the machupo virus attachment glycoprotein. J Virol. 83: 8259-8265.
7. Bowden TA, Crispin M, Harvey DJ, Aricescu AR, Grimes JM, Jones EY, Stuart DI. 2008. Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: A template for antiviral and vaccine design. J Virol. 82: 11628-11636.
8. Burton DR. 2002. Antibodies, viruses and vaccines. Nat Rev Immunol. 2: 706-713.
9. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. 2004. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 5: 233-236.
10. Burton DR, Stanfield RL, Wilson IA. 2005. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA. 102: 14943-14948.
11. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA. 102: 13372-13377.
12. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 300: 2065-2071.
13. Chang VT, Crispin M, Aricescu AR, Harvey DJ, Nettleship JE, Fennelly JA, Yu C, Boles KS, Evans EJ, Stuart DI, Dwek RA, Jones EY, Owens RJ, Davis SJ. 2007. Glycoprotein structural genomics: Solving the glycosylation problem. Structure. 15: 267-273.
14. Crispin M, Chang VT, Harvey DJ, Dwek RA, Evans EJ, Stuart DI, Jones EY, Lord JM, Spooner RA, Davis SJ. 2009. A human embryonic kidney 293T cell line mutated at the Golgi a-mannosidase II locus. J Biol Chem. 284: 21684-21695.
15. Crispin M, Harvey DJ, Chang VT, Yu C, Aricescu AR, Jones EY, Davis SJ, Dwek RA, Rudd PM. 2006. Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology. 16: 748-756.
16. Cutalo JM, Deterding LJ, Tomer KB. 2004. Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom. 15: 1545-1555.
17. Deeks SG, Schweighardt B, Wrin T, Galovich J, Hoh R, Sinclair E, Hunt P, McCune JM, Martin JN, Petropoulos CJ, Hecht FM. 2006. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: Evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol. 80: 6155-6164.
18. Domon B, Costello CE. 1988. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconjugate J. 5: 397-409.
19. Dudkin VY, Orlova M, Geng X, Mandal M, Olson WC, Danishefsky SJ. 2004. Toward fully synthetic carbohydrate-based HIV antigen design: On the critical role of bivalency. J Am Chem Soc. 126: 9560-9562.
20. Dunlop DC, Ulrich A, Appelmelk BJ, Burton DR, Dwek RA, Zitzmann N, Scanlan CN. 2008. Antigenic mimicry of the HIV envelope by AIDS-associated pathogens. AIDS. 22: 2214-2217.
21. Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, Little SJ, Richman DD. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci USA. 102: 18514-18519. (Pubitemid 43011257)
22. Geyer H, Kempf R, Schott HH, Geyer R. 1990. Glycosylation of the envelope glycoprotein from a polytropic murine retrovirus in two different host cells. Eur J Biochem. 193: 855-862.
23. Gupta RK, Rost BE, Relyveld E, Siber GR. 1995. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 6: 229-248.
24. Harvey DJ. 2005a. Fragmentation of negative ions from carbohydrates: Part 1. Use of nitrate and other anionic adducts for the production of negative ion electrospray spectra from N-linked carbohydrates. J Am Soc Mass Spectrom. 16: 622-630.
25. Harvey DJ. 2005b. Fragmentation of negative ions from carbohydrates: Part 2. Fragmentation ofhigh-mannose N-linked glycans. J Am Soc Mass Spectrom. 16: 631-646.
26. Harvey DJ. 2005c. Fragmentation of negative ions from carbohydrates: Part 3. Fragmentation of hybrid and complex N-linked glycans. J Am Soc Mass Spectrom. 16: 647-659.
27. Harvey DJ. 2005d. Structural determination of N-linked glycans by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Proteomics. 5: 1774-1786.
28. Harvey DJ, Merry AH, Royle L, Campbell MP, Dwek RA, Rudd PM. 2009. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics. 9: 3796-3801.
29. Harvey DJ, Royle L, Radcliffe CM, Rudd PM, Dwek RA. 2008. Structural and quantitative analysis of N-linked glycans by matrix-assisted laser desorption ionization and negative ion nanospray mass spectrometry. Anal Biochem. 376: 44-60.
30. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 15: 951-954.
31. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. 2009. Broadly neutralizing human anti- HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5: e1000433.
32. Küster B, Wheeler SF, Hunter AP, Dwek RA, Harvey DJ. 1997. Sequencing of N-linked oligosaccharides directly from protein gels: In-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal Biochem. 250: 82-101.
33. Lee HK, Scanlan CN, Huang CY, Chang AY, Calarese DA, Dwek RA, Rudd PM, Burton DR, Wilson IA, Wong CH. 2004. Reactivity-based one-pot synthesis of oligomannoses: Defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl. 43: 1000-1003.
34. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y. 2008. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J Virol. 82: 6447-6457.
35. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 6: 207-210.
36. Muller WE, Bachmann M, Weiler BE, Schroder HC, Uhlenbruck G, Shinoda T, Shimizu H, Ushijima H. 1991. Antibodies against defined carbohydrate structures of Candida albicans protect H9 cells against infection with human immunodeficiency virus-1 in vitro. J Acquir Immune Defic Syndr. 4: 694-703.
37. Palma AS, Feizi T, Zhang Y, Stoll MS, Lawson AM, Diaz-Rodríguez E, Campanero-Rhodes AS, Costa J, Brown GD, Chai W. 2006. Ligands for the beta-glucan receptor, Dectin-1, assigned using 'designer' microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysac-charides. J Biol Chem. 281: 5771-5779.
38. Pantophlet R, Burton DR. 2006. GP120: Target for neutralizing HIV-1 antibodies. Annu Rev Immunol. 24: 739-769.
39. Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett. 57: 105-112.
40. Parren PW, Moore J, Burton DR, Sattentau QJ. 1999. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity. Aids. 13 Suppl A S137-162.
41. Petrescu AJ, Petrescu SM, Dwek RA, Wormald MR. 1999. A statistical analysis of N- and O-glycan linkage conformations from crystallographic data. Glycobiology. 9: 343-352.
42. Reeves PJ, Callewaert N, Contreras R, Khorana HG. 2002. Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosa- minyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci USA. 99: 13419-13424.
43. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol. 76: 7293-7305.
44. Scanlan CN, Offer J, Zitzmann N, Dwek RA. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature. 446: 1038-1045.
45. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2mannose residues on the outer face of gp120. J Virol. 76: 7306-7321.
46. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, Singer BB, Lucka L, Wormald MR, Wentworth P Jr, Zitzmann N, Rudd PM, Burton DR, Dwek RA. 2007. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specificantibody. J Mol Biol. 372: 16-22.
47. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, Lehrman JK, Boaz M, Tarragona-Fiol T, Miiro G, Birungi J, Pozniak A, McPhee DA, Manigart O, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Walker LM, Poignard P, Wrin T, Fast PE, Burton DR, Koff WC. 2009. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high- throughput neutralization assay together with an analytical selection algorithm. J Virol. 83: 7337-7348.
48. Tomiyama T, Lake D, Masuho Y, Hersh EM. 1991. Recognition of human immunodeficiency virus glycoproteins by natural anti-carbohydrate antibodies in human serum. Biochem Biophys Res Commun. 177: 279-285.
49. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Miiro G, Serwanga J, Pozniak A, McPhee D, Manigart O, Mwananyanda L, Karita E, Inwoley A, Jaoko W, Dehovitz J, Bekker LG, Pitisuttithum P, Paris R, Allen S, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326: 285-289.
50. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature. 422: 307-312.
51. Willison HJ. 2005. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst. 10: 94-112.
52. Woods RJ, Pathiaseril A, Wormald MR, Edge CJ, Dwek RA. 1998. The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur J Biochem. 258: 372-386.
53. Wormald MR, Petrescu AJ, Pao YL, Glithero A, Elliott T, Dwek RA. 2002. Conformational studies of oligosaccharides and glycopeptides: Complementarity of NMR, X-ray crystallography, and molecular modelling. Chem Rev. 102: 371-386.
54. Zhu X, Borchers C, Bienstock RJ, Tomer KB. 2000. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry. 39: 11194-11204.